Cellebrite (CLBT) investor relations material

Executive summary

• Q3 ARR reached $528.5 million, up 20% YoY, and revenue was $149.0 million, up 18%; ARR, revenue and adjusted EBITDA exceeded guidance.

• International growth, accelerating U.S. Federal demand and Genesis traction supported performance; FY26 ARR guidance was reaffirmed and adjusted EBITDA guidance raised.

Financial highlights

• Subscription revenue was $134.9 million, up 20% YoY and 91% of revenue; non-GAAP gross profit was $127.7 million at an 85.7% margin.

• Adjusted EBITDA rose 42% to $53.6 million; adjusted EBITDA margin was 36.0%, versus 29.9% in Q3 2025.

• GAAP net income was $26.7 million and non-GAAP net income was $45.6 million; GAAP diluted EPS was $0.10 and non-GAAP diluted EPS was $0.17.

• Q3 free cash flow was $51.8 million; trailing-12-month free cash flow was $166.0 million.

Outlook and guidance

• FY26 ARR outlook was reaffirmed at $550 million–$560 million, representing 14%–16% YoY growth; confidence is higher at the lower end amid seasonality and large-deal timing.

• FY26 revenue guidance is $553 million–$558 million, up 16%–17%; the outlook reflects more ratable cloud and AI revenue and less hardware revenue.

• FY26 adjusted EBITDA guidance was raised to $163 million–$166 million, with a 29%–30% margin; full-year FCF margin is expected at ~30%.

• Q4 revenue guidance is $145 million–$150 million and adjusted EBITDA guidance is $47 million–$50 million, with a 32%–33% margin.